Sam joined Apposite Capital in 2007. He has been particularly involved in all of Apposite’s healthcare services and health IT investments and served on portfolio Boards in both the US and Europe. He has worked in deal-making in the healthcare sector since 2000 when he joined Deutsche Bank’s mergers and acquisitions practice, working with a number of multinational clients on corporate divestitures and acquisitions, including public takeovers and leveraged buy-outs. Sam then joined the Business Development team at Belgian pharmaceutical company, UCB, where he was instrumental in global product licensing and M&A, including UCB’s $2.7bn acquisition of the UK public biotech company, Celltech. Sam has a first degree in Natural Sciences and a masters degree in Chemistry from Cambridge University, as well as an MBA from Harvard Business School.